X4 Pharmaceuticals (XFOR) FCF Margin (2018 - 2025)
X4 Pharmaceuticals posted quarterly FCF Margin of 623.4% for Q4 2025, up 168036.0% year-on-year from N/an in Q4 2024, and up 60.41% on a QoQ basis from 1574.56% in Q3 2025.
X4 Pharmaceuticals (XFOR) has 4 years of FCF Margin data on file, last reported at 623.4% in Q4 2025.
- For the quarter ending Q4 2025, FCF Margin rose 168036.0% year-over-year to 623.4%; the trailing twelve-month figure through Dec 2025 stood at 245.21% (up 620180.0% YoY), and the FY2025 full-year result was 245.21%, up 488686.0% from the prior year.
- FCF Margin for Q4 2025 stood at 623.4%, up from 1574.56% in the prior quarter.
- Across five years, FCF Margin topped out at 43.05% in Q1 2025 and bottomed at 11373.71% in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 4.17% |
| 10 | X4 Pharmaceuticals | 182.28 Mn | 182.28 Mn | 2.20 Mn | -623.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -623.40% |
| Sep 30, 2025 | -1,574.56% |
| Jun 30, 2025 | -1,515.46% |
| Mar 31, 2025 | -43.05% |
| Dec 31, 2024 | -2,303.77% |
| Sep 30, 2024 | -6,093.57% |
| Jun 30, 2024 | -11,373.71% |
| Mar 31, 2020 | -517.57% |
| Dec 31, 2018 | -192.40% |